Expertise in
37
conditions

Dr. Carolyn Mulroney

Hematology
Sarah Cannon Transplant And Cellular Therapy Program At MountainView Hospital Outpatient Clinic
3150 N Tenaya Way Ste 520, 
Las Vegas, NV 
Accepting New Patients
Expertise in
37
conditions
Sarah Cannon Transplant And Cellular Therapy Program At MountainView Hospital Outpatient Clinic
3150 N Tenaya Way Ste 520, 
Las Vegas, NV 

Overview

Carolyn Mulroney is a Hematologist in Las Vegas, Nevada. Dr. Mulroney is highly rated in 37 conditions, according to our data. Her top areas of expertise are Multiple Myeloma, Non-Hodgkin Lymphoma, Follicular Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Mulroney is currently accepting new patients.

Her clinical research consists of co-authoring 19 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology

Licenses

Internal Medicine in NV

Hospital Affiliations

Mountainview Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health Group
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Sarah Cannon Transplant and Cellular Therapy Program at MountainView Hospital Outpatient Clinic
3150 N Tenaya Way Ste 520, Las Vegas, NV 89128

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Pilot Phase I Study of Atezolizumab (MPDL3280A) in Combination With Immunogenic Chemotherapy (Gemcitabine-Oxaliplatin) and Rituximab for Transformed Diffuse Large B-Cell Lymphoma
A Pilot Phase I Study of Atezolizumab (MPDL3280A) in Combination With Immunogenic Chemotherapy (Gemcitabine-Oxaliplatin) and Rituximab for Transformed Diffuse Large B-Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Biological, Drug
Study Drugs: Atezolizumab, Gemcitabine, Oxaliplatin, Rituximab
Study Phase: Phase 1
A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
Enrollment Status: Active_not_recruiting
Publish Date: January 26, 2026
Intervention Type: Biological, Procedure
Study Drug: Rituximab
Study Phase: Phase 3
Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial (BELINDA)
Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial (BELINDA)
Enrollment Status: Active_not_recruiting
Publish Date: January 06, 2026
Intervention Type: Drug
Study Drugs: Tisagenlecleucel, Platinum-based immunochemotherapy, high dose chemotherapy
Study Phase: Phase 3
A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, UCB-derived, Stem and Progenitor Cells, vs. Unmanipulated UCB for Patients With Hematological Malignancies
A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, UCB-derived, Stem and Progenitor Cells, vs. Unmanipulated UCB for Patients With Hematological Malignancies
Enrollment Status: Completed
Publish Date: April 06, 2025
Intervention Type: Drug, Other
Study Drug: Omidubicel
Study Phase: Phase 3
A Multi-Center Phase II Trial of Ibrutinib Plus Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma
A Multi-Center Phase II Trial of Ibrutinib Plus Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma
Enrollment Status: Completed
Publish Date: March 26, 2025
Intervention Type: Drug
Study Drugs: Brentuximab Vedotin, Ibrutinib
Study Phase: Phase 2
A Phase 3 Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of AB-205 Plus Standard of Care Versus Placebo Plus Standard of Care in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT) (E-CELERATE)
A Phase 3 Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of AB-205 Plus Standard of Care Versus Placebo Plus Standard of Care in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT) (E-CELERATE)
Enrollment Status: Terminated
Publish Date: February 04, 2025
Intervention Type: Other, Biological
Study Drug: AB-205
Study Phase: Phase 3
A Study to Evaluate the Long-Term Safety of CLBR001, A Lentiviral Based Chimeric Antigen Receptor, In Patients With B-Cell Malignancies Previously Administered CLBR001
A Study to Evaluate the Long-Term Safety of CLBR001, A Lentiviral Based Chimeric Antigen Receptor, In Patients With B-Cell Malignancies Previously Administered CLBR001
Enrollment Status: Enrolling_by_invitation
Publish Date: January 10, 2025
Intervention Type: Combination product
Study Drugs: CLBR001 CAR-T Cells, SWI019
Study Phase: Phase 1
A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)
A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)
Enrollment Status: Active_not_recruiting
Publish Date: November 06, 2024
Intervention Type: Other, Drug, Biological
Study Drugs: Bleomycin, Brentuximab, Dacarbazine, Doxorubicin, Nivolumab, Vinblastine
Study Phase: Phase 2
A Phase 1, Open-label, Dose Escalating Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the Combination of CLBR001 and SWI019 in Patients With Relapsed/Refractory B-cell Malignancies
A Phase 1, Open-label, Dose Escalating Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the Combination of CLBR001 and SWI019 in Patients With Relapsed/Refractory B-cell Malignancies
Enrollment Status: Completed
Publish Date: August 20, 2024
Intervention Type: Combination product
Study Drugs: CLBR001 CAR-T Cells, SWI019
Study Phase: Phase 1
A Phase III, Multicenter, Randomized Controlled Study to Compare Safety and Efficacy of a Haploidentical HSCT and Adjunctive Treatment With ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted ex Vivo of Host Alloreactive T-cells, Versus a Haploidentical HSCT With Post-transplant Cyclophosphamide in Patients With a Hematologic Malignancy
A Phase III, Multicenter, Randomized Controlled Study to Compare Safety and Efficacy of a Haploidentical HSCT and Adjunctive Treatment With ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted ex Vivo of Host Alloreactive T-cells, Versus a Haploidentical HSCT With Post-transplant Cyclophosphamide in Patients With a Hematologic Malignancy
Enrollment Status: Terminated
Publish Date: May 24, 2022
Intervention Type: Drug, Biological, Procedure
Study Drugs: ATIR101 Ex Vivo-Depleted T Lymphocyte-Enriched Leukocyte, Cyclophosphamide
Study Phase: Phase 3
View 9 Less Clinical Trials

19 Total Publications

Treatment of an Indolent T-Cell Lymphoma of the Gastrointestinal Tract Harboring STAT3::JAK2 With Jakafi (Ruxolitinib) With Significant Clinical Improvements.
Treatment of an Indolent T-Cell Lymphoma of the Gastrointestinal Tract Harboring STAT3::JAK2 With Jakafi (Ruxolitinib) With Significant Clinical Improvements.
Journal: EJHaem
Published: January 06, 2025
Similar Doctors
Clark Jean
Expertise in
132
conditions
Dr. Clark Jean
Hematology
Expertise in
132
conditions
Dr. Clark Jean
Hematology

Comprehensive Cancer Centers Of Nevada

7445 Peak Dr, 
Las Vegas, NV 
 (0.6 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Clark Jean is a Hematologist in Las Vegas, Nevada. Dr. Jean is highly rated in 132 conditions, according to our data. His top areas of expertise are Acute Mountain Sickness, Iron Deficiency Anemia, Lung Cancer, Pleuropulmonary Blastoma, and Bone Marrow Aspiration. Dr. Jean is currently accepting new patients.

Expertise in
33
conditions
Dr. Aaron Goodman
Hematology
Expertise in
33
conditions
Dr. Aaron Goodman
Hematology

Sarah Cannon Transplant And Cellular Therapy Program At MountainView Hospital Outpatient Clinic

3150 N Tenaya Way Ste 520, 
Las Vegas, NV 
 (1.6 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Aaron Goodman is a Hematologist in Las Vegas, Nevada. Dr. Goodman is highly rated in 33 conditions, according to our data. His top areas of expertise are Rosai-Dorfman Disease, Smoldering Multiple Myeloma, Multiple Myeloma, Tissue Biopsy, and Bone Marrow Aspiration. Dr. Goodman is currently accepting new patients.

Wolfram Samlowski
Expertise in
49
conditions
Dr. Wolfram Samlowski
Hematology
Expertise in
49
conditions
Dr. Wolfram Samlowski
Hematology

Comprehensive Cancer Centers Of Nevada

9280 W Sunset Rd, Ste 100, 
Las Vegas, NV 
 (10.3 miles away)
702-952-1251
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Telehealth visits are available Wolfram Samlowski, MD, FACP is a medical oncologist at Comprehensive Cancer Centers of Nevada (CCCN) specializing in melanoma and renal cancer. He is board certified in internal medicine and medical oncology. Dr. Samlowski performs cancer immunotherapy and other oncology procedures at Southern Hills Hospital in Las Vegas. His mission is to provide access to both the best standard options and new drugs for difficult to treat diseases.My goal is to provide access to both the best standard options and new drugs in development for challenging diseases. Dr. Samlowski is highly rated in 49 conditions, according to our data. His top areas of expertise are Melanoma, Adult Soft Tissue Sarcoma, Renal Cell Carcinoma (RCC), Mesenchymoma, and Vitrectomy.

Frequently Asked Questions about Dr. Carolyn Mulroney

Is Dr. Carolyn Mulroney a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Carolyn Mulroney is classified as an Distinguished expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Carolyn Mulroney specialize in?

While Dr. Carolyn Mulroney is a Hematology, they have specific expertise in Multiple Myeloma, Non-Hodgkin Lymphoma, and Follicular Lymphoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Carolyn Mulroney participate in research or clinical trials?

Yes. Dr. Carolyn Mulroney has published 19 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Dr. Carolyn Mulroney's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Carolyn Mulroney accept my insurance?

Dr. Carolyn Mulroney accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mulroney's expertise for a condition
ConditionClose
    View All 32 Advanced Conditions
    View All 55 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile